Comparing Revenue Performance: Supernus Pharmaceuticals, Inc. or Evotec SE?

A Decade of Revenue Growth: Supernus Pharmaceuticals vs. Evotec SE

In the competitive landscape of pharmaceuticals, revenue growth is a key indicator of success. From 2014 to 2023, Evotec SE and Supernus Pharmaceuticals, Inc. have shown remarkable trajectories. Evotec SE's revenue surged by over 770%, starting from approximately $89 million in 2014 to nearly $781 million in 2023. Meanwhile, Supernus Pharmaceuticals experienced a robust growth of around 400%, with revenues climbing from $122 million to $608 million over the same period.

Key Insights

Evotec SE consistently outpaced Supernus Pharmaceuticals, particularly from 2018 onwards, where it maintained a lead in revenue. The year 2022 marked a peak for both companies, with Evotec SE reaching its highest revenue, while Supernus Pharmaceuticals also saw significant gains. This data highlights the dynamic nature of the pharmaceutical industry and the importance of strategic growth initiatives.